Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase
Huang D, Tran A, Yeh ML, Yasuda S, Tsai PC, Pei-Chien H, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology 78(5):p 1558-1568, November 2023. | DOI: 10.1097/HEP.0000000000000459 Πατώντας ΕΔΩ μπορείτε να δείτε το άρθρο
Λεπτομέρειες